Epidemiology, resource use, and treatment patterns of locally advanced or metastatic urothelial carcinoma in France.

ABSTRACT:

Aim

Describe real-world epidemiology, treatment patterns, health care resource utilization, and costs of locally advanced or metastatic urothelial carcinoma (la/mUC) in France.

Patients & methods

Retrospective study including all adults with la/mUC diagnosis during January 2017 to December 2020 in the PMSI database.

Results

Annual prevalence and incidence ranged from 36.4 to 38.9 and 16.4 to 18.5 cases per 100,000 people, respectively. Of the 25,314 patients with incident la/mUC, 37.6% did not receive first-line systemic treatment. Of the 14,656 patients who started first-line systemic treatment, 66.6%, 22.5%, and 10.9% received 1, 2, and 3 lines of therapy, respectively. Annual per-patient costs in second-/third-line setting ranged from €8803 to €16,012.

Conclusio

SUBMITTER: Joly F 

PROVIDER: S-EPMC11881851 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature